Drug-Induced Liver Injury from Statins

Lindsay Meurer, Stanley Martin Cohen

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations

Abstract

The hydroxymethyglutaryl-coenzyme A reductase inhibitors (statins) are a commonly prescribed class of medication for the treatment of hyperlipidemia and coronary artery disease. This class of medication has several proven benefits, including reduction of mortality related to coronary artery disease. A major consideration when prescribing these drugs are the potential for adverse effects, mainly myalgias, myopathy, and hepatotoxicity. In this article, we summarize current data on statin-associated hepatotoxicity and highlight that the risk of clinically significant idiosyncratic drug-induced liver injury is actually quite small. We also review preclinical data suggesting potential hepatoprotective effects of statin therapy.

Original languageEnglish
Pages (from-to)107-119
Number of pages13
JournalClinics in Liver Disease
Volume24
Issue number1
DOIs
StatePublished - Feb 2020

Keywords

  • Drug-induced liver injury (DILI)
  • Hepatotoxicity
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Liver function test
  • Statins

Fingerprint

Dive into the research topics of 'Drug-Induced Liver Injury from Statins'. Together they form a unique fingerprint.

Cite this